Advertisement
Advertisement
IBIO
iBio, Inc. Common Stock
0.74
USDSponsored
+0.01
+1.16%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.77
+0.03
+4.12%
iBio, Inc. Common Stock (IBIO) Earnings
IBIO Earnings Reports
Positive Surprise Ratio
IBIO beat 8 of 20 last estimates.
40%
Next Report
Next Week
Date of Next Report
Nov 10, 2026
Estimate for Q1 27 (Revenue/ EPS)
$20.40K
/-$0.07
Implied change from Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
-79.60%
/-36.36%
iBio, Inc. Common Stock earnings per share and revenue
On Aug 28, 2026, IBIO reported earnings of -0.07 USD per share (EPS) for Q4 26, missing the estimate of -0.06 USD, resulting in a -7.69% surprise. Revenue reached --, compared to an expected 58.28 thousand, with a -100.00% difference. The market reacted with a -2.86% price change (close before vs. close after earnings).
Looking ahead to Q1 27, 3 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 20.40 thousand USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were iBio, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, iBio, Inc. Common Stock reported EPS of -$0.07, missing estimates by -7.69%, and revenue of $0.00, -100% below expectations.
How did the market react to iBio, Inc. Common Stock's Q4 2026 earnings?
The stock price moved down -2.86%, changed from $1.40 before the earnings release to $1.36 the day after.
When is iBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for iBio, Inc. Common Stock's next earnings report?
Based on 3
analysts, iBio, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $20.40K for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.